P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CD19 CAR T‐CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CD19 CAR T‐CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE

Saved in:
Bibliographic Details
Published in:HemaSphere Vol. 6; no. Suppl; pp. 1330 - 1331
Main Authors: Bücklein, V., Perez, A., Iacoboni, G., Rejeski, K., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., Bergwelt, M., Barba, P., Jain, M. D., Subklewe, M.
Format: Journal Article
Language:English
Published: Philadelphia, PA Lippincott Williams & Wilkins 23-06-2022
Wiley
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000848644.19354.c7